These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 25537338

  • 1. A novel injection strategy of flurbiprofen axetil by inhibiting protein binding with 6-methoxy-2-naphthylacetic acid.
    Ogata K, Takamura N, Tokunaga J, Ikeda T, Setoguchi N, Tanda K, Yamasaki T, Nishio T, Kawai K.
    Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):179-86. PubMed ID: 25537338
    [Abstract] [Full Text] [Related]

  • 2. Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats.
    Ogata K, Takamura N, Tokunaga J, Kawai K, Arimori K, Higuchi S.
    J Pharm Pharmacol; 2008 Jan; 60(1):15-20. PubMed ID: 18088500
    [Abstract] [Full Text] [Related]

  • 3. Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites.
    Nobilis M, Mikušek J, Szotáková B, Jirásko R, Holčapek M, Chamseddin C, Jira T, Kučera R, Kuneš J, Pour M.
    J Pharm Biomed Anal; 2013 Jun; 80():164-72. PubMed ID: 23584048
    [Abstract] [Full Text] [Related]

  • 4. Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses.
    Soma LR, Uboh CE, Rudy JA, Smith MS.
    Am J Vet Res; 1996 Apr; 57(4):517-21. PubMed ID: 8712517
    [Abstract] [Full Text] [Related]

  • 5. A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes.
    Matsumoto K, Hasegawa T, Ohara K, Takei C, Kamei T, Koyanagi J, Takahashi T, Akimoto M.
    Xenobiotica; 2020 Jul; 50(7):783-792. PubMed ID: 31855101
    [Abstract] [Full Text] [Related]

  • 6. In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone.
    Matsumoto K, Nemoto E, Hasegawa T, Akimoto M, Sugibayashi K.
    Biol Pharm Bull; 2011 Jul; 34(5):734-9. PubMed ID: 21532165
    [Abstract] [Full Text] [Related]

  • 7. Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer-Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid in vitro.
    Matsumoto K, Hasegawa T, Ohara K, Kamei T, Koyanagi J, Akimoto M.
    Xenobiotica; 2021 Feb; 51(2):155-166. PubMed ID: 33146575
    [Abstract] [Full Text] [Related]

  • 8. Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery.
    Miehlke RK, Schneider S, Sörgel F, Muth P, Henschke F, Giersch KH, Münzel P.
    Drugs; 1990 Feb; 40 Suppl 5():57-61. PubMed ID: 2081495
    [Abstract] [Full Text] [Related]

  • 9. An evaluation of an anti-inflammatory-histamine H2 antagonist drug complex on gastric erosions in the rat.
    Imai T, Fukuhara A, Ueda I, Otagiri M.
    J Pharmacol Exp Ther; 1993 Apr; 265(1):328-33. PubMed ID: 8097246
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Potential of Piperazinylalkylester Prodrugs of 6-Methoxy-2-Naphthylacetic Acid (6-MNA) for Percutaneous Drug Delivery.
    Pawar V, Thosani R, Kanhed A, Giridhar R, Yadav MR.
    AAPS PharmSciTech; 2015 Jun; 16(3):518-27. PubMed ID: 25370023
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis.
    Setoguchi N, Takamura N, Fujita K, Ogata K, Tokunaga J, Nishio T, Chosa E, Arimori K, Kawai K, Yamamoto R.
    Biopharm Drug Dispos; 2013 Mar; 34(2):125-36. PubMed ID: 23225308
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of the antiinflammatory prodrug, nabumetone and its principal active metabolite on rat gastric mucosal, aortic and platelet eicosanoid synthesis, in vitro and ex vivo.
    Jeremy JY, Thompson CS, Mikhailidis DP, Dandona P.
    Prostaglandins Leukot Essent Fatty Acids; 1990 Nov; 41(3):195-9. PubMed ID: 2281122
    [Abstract] [Full Text] [Related]

  • 18. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.
    Turpeinen M, Hofmann U, Klein K, Mürdter T, Schwab M, Zanger UM.
    Drug Metab Dispos; 2009 May; 37(5):1017-24. PubMed ID: 19204080
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.